Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia

F K Habib; M Ross; R Tate; G D Chisholm

doi:10.1046/j.1365-2265.1997.950908.x

Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia

F K Habib, M Ross, R Tate, G D Chisholm

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.

Original language	English
Pages (from-to)	137-44
Number of pages	8
Journal	Clinical Endocrinology
Volume	46
Issue number	2
DOIs	https://doi.org/10.1046/j.1365-2265.1997.950908.x
Publication status	Published - 1997

Keywords

5-alpha reductase inhibitors
aged
androgens
androstenedione
dihydrotestosterone
double-blind method
finasteride
humans
prostate
prostate-specific antigen
prostatic hyperplasia
testosterone

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1046/j.1365-2265.1997.950908.x

Cite this

@article{332b1b1216c249b7b8e122818d1336c0,

title = "Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia",

abstract = "The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.",

keywords = "5-alpha reductase inhibitors, aged, androgens, androstenedione, dihydrotestosterone, double-blind method, finasteride, humans, prostate, prostate-specific antigen, prostatic hyperplasia, testosterone",

author = "Habib, {F K} and M Ross and R Tate and Chisholm, {G D}",

year = "1997",

doi = "10.1046/j.1365-2265.1997.950908.x",

language = "English",

volume = "46",

pages = "137--44",

journal = "Clinical Endocrinology",

issn = "0300-0664",

number = "2",

}

TY - JOUR

T1 - Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia

AU - Habib, F K

AU - Ross, M

AU - Tate, R

AU - Chisholm, G D

PY - 1997

Y1 - 1997

N2 - The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.

AB - The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.

KW - 5-alpha reductase inhibitors

KW - aged

KW - androgens

KW - androstenedione

KW - dihydrotestosterone

KW - double-blind method

KW - finasteride

KW - humans

KW - prostate

KW - prostate-specific antigen

KW - prostatic hyperplasia

KW - testosterone

U2 - 10.1046/j.1365-2265.1997.950908.x

DO - 10.1046/j.1365-2265.1997.950908.x

M3 - Article

C2 - 9135694

VL - 46

SP - 137

EP - 144

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -

Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this